PFE - Pharma and biotech deal values spike 35% in 2023: report
2023-12-28 15:06:23 ET
More on AbbVie, Amgen, etc.
- The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations
- Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase
- Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management
- FDA’s new drug approvals for 2023 rise 51% from last year
- LegoChem signs antibody deal with Amgen worth up to $1.25B
For further details see:
Pharma and biotech deal values spike 35% in 2023: report